Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | SI | P14410 | 1/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.50 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953510 | 0.95 | GAA (0.59) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL12889915 | 0.92 | GAA (0.57) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL13816288 | 0.89 | GAA (0.50) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL24414090 | 0.89 | GAA (0.48) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL24413823 | 0.87 | GAA (0.47) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL28166632 | 0.84 | GAA (0.49) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL17861691 | 0.83 | GAA (0.50) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL14646980 | 0.83 | POLB (0.60) | GAAMGAMSIMGAM2POLB | |
| Thymoquinol Dimethylether SCHEMBL12613923 | 0.83 | POLB (0.66) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL12412395 | 0.83 | POLB (0.60) | GAAMGAMSIMGAM2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098879-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2020227437-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2019028456-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2916840-B1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | NUCORION PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9744186-B2 | Substituted gemcitabine aryl amide analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014074725-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | OHIO STATE INNOVATION FOUNDATION (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8703804-B2 | Ryanodine receptor inhibitors and methods relating thereto | UTI LIMITED PARTNERSHIP (CA) | 2014-04-22 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070254849-A1 | Ryanodine receptor inhibitors and methods relating thereto | UTI LIMITED PARNERSHIP | 2007-11-01 | — | — | US | disclosed |
| US-20070254849-A1 | Ryanodine receptor inhibitors and methods relating thereto | UTI LIMITED PARNERSHIP | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | GAA 2915/4885MGAM 4877/4885SI 4662/4885 |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | GAA 641/4885MGAM 1194/4885SI 43/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | GAA 2915/4885MGAM 4877/4885SI 4662/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | GAA 641/4885MGAM 1194/4885SI 43/4885 |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | KCNJ1, KCNJ2, KCNJ11 | GAA 1082/4885MGAM 4049/4885SI 3605/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | GAA 1095/4885MGAM 143/4885SI 1429/4885 |
| US-20070254849-A1 | Ryanodine receptor inhibitors and methods relating thereto | RYR2, RYR1, ATP2A1 | GAA 2374/4885MGAM 4360/4885SI 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.